BRPI0906404B8 - construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno - Google Patents
construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígenoInfo
- Publication number
- BRPI0906404B8 BRPI0906404B8 BRPI0906404A BRPI0906404A BRPI0906404B8 BR PI0906404 B8 BRPI0906404 B8 BR PI0906404B8 BR PI0906404 A BRPI0906404 A BR PI0906404A BR PI0906404 A BRPI0906404 A BR PI0906404A BR PI0906404 B8 BRPI0906404 B8 BR PI0906404B8
- Authority
- BR
- Brazil
- Prior art keywords
- well
- proliferation
- antigen
- ligand
- receptor
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000002101 lytic effect Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000010276 construction Methods 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K14/592—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH] at least 1 amino acid in D-form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
Abstract
constructo de fusão com domínio lítico, composições, dosagem unitária e kit compreendendo o mesmo, bem como seus usos e peptídeo. a presente invenção refere-se a constructos de fusão, a processos de utilização de constructos de fusão e a processos de tratamento de proliferação celular ou distúrbios hiperproliferativos indesejáveis ou aberrantes, tais como tumores, cânceres, neoplasia e malignidades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2337708P | 2008-01-24 | 2008-01-24 | |
US61/023,377 | 2008-01-24 | ||
PCT/US2009/031999 WO2009094634A1 (en) | 2008-01-24 | 2009-01-26 | Lytic domain fusion constructs and methods of making and using same |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0906404A2 BRPI0906404A2 (pt) | 2015-11-24 |
BRPI0906404B1 BRPI0906404B1 (pt) | 2021-04-06 |
BRPI0906404B8 true BRPI0906404B8 (pt) | 2021-05-25 |
Family
ID=40671139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0906404A BRPI0906404B8 (pt) | 2008-01-24 | 2009-01-26 | construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno |
Country Status (13)
Country | Link |
---|---|
US (4) | US8318899B2 (pt) |
EP (1) | EP2252627B1 (pt) |
JP (1) | JP5616233B2 (pt) |
KR (2) | KR101863136B1 (pt) |
CN (1) | CN102089320B (pt) |
AU (1) | AU2009206212B2 (pt) |
BR (1) | BRPI0906404B8 (pt) |
CA (1) | CA2713126C (pt) |
DK (1) | DK2252627T3 (pt) |
ES (1) | ES2633453T3 (pt) |
IL (2) | IL207181A (pt) |
PT (1) | PT2252627T (pt) |
WO (1) | WO2009094634A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011031477A2 (en) * | 2009-08-25 | 2011-03-17 | Esperance Pharmaceuticals, Inc. | Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same |
US10093961B2 (en) * | 2009-12-22 | 2018-10-09 | Esperance Pharmaceuticals | Methods for diagnosis of and predicting treatment efficacy of hormone receptor expressing tumors, cancers and neoplasias |
CN104177501A (zh) * | 2010-02-09 | 2014-12-03 | 沈阳药科大学 | 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法 |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
WO2011137245A2 (en) * | 2010-04-30 | 2011-11-03 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
WO2012050892A2 (en) * | 2010-09-29 | 2012-04-19 | Esperance Pharmaceuticals, Inc. | Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors |
US8461118B2 (en) * | 2011-07-07 | 2013-06-11 | Tuskegee University | Lytic peptides having anti-proliferative activity against prostate cancer cells |
PT2771364T (pt) | 2011-10-27 | 2019-09-10 | Genmab As | Produção de proteínas heterodiméricas |
PL397167A1 (pl) * | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
PL223487B1 (pl) * | 2011-12-28 | 2016-10-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
CA2870200A1 (en) * | 2012-04-12 | 2013-10-17 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
WO2014061419A1 (ja) | 2012-10-17 | 2014-04-24 | 公立大学法人奈良県立医科大学 | 新規癌マーカーおよびその利用 |
KR20210090298A (ko) * | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
JP2016506373A (ja) * | 2012-11-15 | 2016-03-03 | エスペランス ファーマシューティカルズ, インコーポレイテッド | 卵胞刺激ホルモン(fsh)/溶解ドメイン融合コンストラクト及びその作製及び使用の方法 |
WO2016054153A1 (en) | 2014-10-02 | 2016-04-07 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
GB2543550A (en) * | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
KR20180123027A (ko) * | 2016-02-12 | 2018-11-14 | 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬추얼 앤드 메카니컬 컬리지 | 암 치료 조합 조성물, 방법 및 용도 |
CN105963687A (zh) * | 2016-04-27 | 2016-09-28 | 张金凤 | 一种用于治疗慢性盆腔疼痛的复方制剂及其制备方法 |
CN107955061B (zh) * | 2017-11-15 | 2021-07-30 | 连云港恒运药业有限公司 | 地加瑞克关键中间体的制备方法 |
BR112022018994A2 (pt) * | 2020-03-26 | 2022-11-29 | A28 Therapeutics Inc | Construtos de fusão de domínio lítico, inibidores de via de sinalização e métodos de produzir e usar os mesmos |
CN112225821B (zh) * | 2020-10-21 | 2021-05-21 | 徐州医科大学 | 一种具有抗肿瘤作用的多肽及其应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3854476T2 (de) | 1987-07-06 | 1996-04-04 | Univ Louisiana State | Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden. |
CA1327311C (en) | 1987-07-06 | 1994-03-01 | Jesse M. Jaynes | Therapeutic antimicrobial polypeptides, their use and methods for preparation |
US5861478A (en) | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
US5792831A (en) | 1990-02-08 | 1998-08-11 | Magainin Pharmaceuticals Inc. | Analogues of magainin peptides containing D-amino acids |
US5459237A (en) | 1990-02-08 | 1995-10-17 | Magainin Pharmaceuticals Inc. | Peptide compositions and uses therefor |
JPH07504152A (ja) | 1990-02-08 | 1995-05-11 | マゲイニン ファーマスーティカルズ, インコーポレーテッド | 生物活性ペプチドおよび標的細胞、ウイルス、あるいはウイルス感染細胞の成長を抑制する方法 |
WO1992022317A1 (en) | 1991-06-12 | 1992-12-23 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides having c-terminal substitutions |
AU3236293A (en) | 1991-12-09 | 1993-07-19 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides and chelating agents |
CA2137087A1 (en) | 1992-06-01 | 1993-12-09 | U. Prasad Kari | Biologically active peptides having n-terminal substitutions |
US6348445B1 (en) | 1992-06-01 | 2002-02-19 | Magainin Pharmaceuticals, Inc. | Biologically active peptides with reduced toxicity in animals and a method for preparing same |
AU5081193A (en) | 1992-08-31 | 1994-03-29 | Magainin Pharmaceuticals, Inc. | Treatment of gynecological malignancies with biologically active peptides |
JPH08507749A (ja) * | 1992-12-03 | 1996-08-20 | マガイニン ファーマシューティカルズ,インク. | 皮膚悪性疾患の生物学的活性を有するペプチドによる治療 |
AU5741794A (en) | 1992-12-07 | 1994-07-04 | Magainin Pharmaceuticals, Inc. | Treatment of septic shock with conjugated biologically active peptides |
AU6251594A (en) | 1993-02-26 | 1994-09-14 | Magainin Pharmaceuticals, Inc. | Treatment of cancerous growths with biologically active peptides and protease inhibitors |
JPH09500102A (ja) | 1993-04-28 | 1997-01-07 | ウォーセスター ファウンデーション フォー エクスペリメンタル バイオロジー | 細胞指向性溶解孔形成剤 |
US5773413A (en) | 1993-06-04 | 1998-06-30 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasias, and lytic peptides therefor |
US5955573A (en) | 1993-06-04 | 1999-09-21 | Demegen, Inc. | Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same |
US5561107A (en) | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
AU7050294A (en) | 1993-06-04 | 1995-01-03 | Demeter Biotechnologies, Ltd. | Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides |
US5968904A (en) | 1993-06-04 | 1999-10-19 | Demegen, Inc. | Modified arginine containing lytic peptides and method of making the same by glyoxylation |
WO1995013085A1 (en) | 1993-11-08 | 1995-05-18 | Demeter Biotechnologies Ltd. | Methylated lysine-rich lytic peptides and method of making same by reductive alkylation |
US5789542A (en) * | 1994-04-22 | 1998-08-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Amphipathic peptides |
IL114697A0 (en) | 1994-07-22 | 1995-11-27 | Demeter Biotech Ltd | Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use |
JP2001501620A (ja) | 1996-10-04 | 2001-02-06 | デメジェン インコーポレイテッド | 免疫不全ウイルス感染の治療方法 |
WO2000053755A2 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
US6566334B1 (en) | 1997-02-06 | 2003-05-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Short amphipathic peptides with activity against bacteria and intracellular pathogens |
AU6587998A (en) * | 1997-03-27 | 1998-10-20 | Demeter Biotechnologies, Ltd. | Ligand/lytic peptide compositions and methods of use |
US6635740B1 (en) * | 1997-03-27 | 2003-10-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Ligand/lytic peptide compositions and methods of use |
GB9711115D0 (en) * | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
WO1999003488A2 (en) | 1997-07-15 | 1999-01-28 | Magainin Pharmaceuticals Inc. | Biologically active peptides with reduced toxicity in animals and a method for preparing same |
US6680058B1 (en) | 1997-09-03 | 2004-01-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for contraception in or sterilization of mammals |
US6461813B2 (en) * | 1998-09-21 | 2002-10-08 | Rigel Pharmaceuticals, Inc. | Multiparameter FACS assays to detect alterations in cell cycle regulation |
EP1075277B2 (en) * | 1998-05-08 | 2012-10-31 | The Regents of the University of California | Methods for detecting and inhibiting angiogenesis |
US6656906B1 (en) * | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
GB0005702D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Method |
PL201898B1 (pl) | 1999-09-23 | 2009-05-29 | Zentaris Gmbh | Zastosowanie antagonisty LH-RH w leczeniu endometriozy |
PL357999A1 (en) | 2000-03-14 | 2004-08-09 | Zentaris Gmbh | Lhrh-antagonists, production and use thereof as medicament |
EP1285081A2 (en) * | 2000-05-30 | 2003-02-26 | ICH Productions Limited | Improved methods of transfection |
US6875744B2 (en) | 2001-03-28 | 2005-04-05 | Helix Biomedix, Inc. | Short bioactive peptides |
CA2467237C (en) | 2001-11-15 | 2011-09-20 | Herman Jan Tijmen Coelingh Bennink | Method of preventing or treating benign gynaecological disorders |
CA2482995C (en) | 2002-04-22 | 2013-01-29 | Dow Global Technologies Inc. | Low-cost production of peptides |
AU2003287950B2 (en) | 2002-09-27 | 2009-01-29 | Zentaris Gmbh | Administration form for pharmaceutically active peptides with sustained release and method for the production thereof |
WO2004045554A2 (en) * | 2002-11-15 | 2004-06-03 | Sangstat Medical Corporation | Cytomodulating peptides for treating interstitial cystitis |
US7091185B2 (en) | 2003-02-24 | 2006-08-15 | Dow Global Technologies Inc. | Periodic antimicrobial peptides |
CN1894277A (zh) | 2003-02-24 | 2007-01-10 | 陶氏环球技术公司 | 周期性抗微生物肽 |
GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
NO20031818D0 (no) | 2003-04-23 | 2003-04-23 | Uni I Tromsoe | Fremgangsmåte av bioaktiv peptid forberedelse |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
GB0320806D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
GB0506759D0 (en) | 2005-04-02 | 2005-05-11 | Medical Res Council | Combination treatment methods |
US20090061006A1 (en) * | 2006-03-31 | 2009-03-05 | Carola Leuschner | Layered Nanoparticles for Sustained Release of Small Molecules |
US7288622B1 (en) | 2006-09-19 | 2007-10-30 | Issar Pharmaceuticals Pvt Ltd | Composition for treatment of burns and wounds |
US7803755B2 (en) | 2006-12-21 | 2010-09-28 | Jesse Jaynes | Molecules for the treatment and prevention of fungal diseases |
-
2009
- 2009-01-26 CN CN200980111383.7A patent/CN102089320B/zh active Active
- 2009-01-26 ES ES09704677.5T patent/ES2633453T3/es active Active
- 2009-01-26 EP EP09704677.5A patent/EP2252627B1/en active Active
- 2009-01-26 WO PCT/US2009/031999 patent/WO2009094634A1/en active Application Filing
- 2009-01-26 JP JP2010544463A patent/JP5616233B2/ja not_active Expired - Fee Related
- 2009-01-26 US US12/359,906 patent/US8318899B2/en active Active
- 2009-01-26 AU AU2009206212A patent/AU2009206212B2/en active Active
- 2009-01-26 KR KR1020167023712A patent/KR101863136B1/ko active IP Right Grant
- 2009-01-26 PT PT97046775T patent/PT2252627T/pt unknown
- 2009-01-26 CA CA2713126A patent/CA2713126C/en not_active Expired - Fee Related
- 2009-01-26 BR BRPI0906404A patent/BRPI0906404B8/pt active IP Right Grant
- 2009-01-26 KR KR1020107018765A patent/KR101749310B1/ko active IP Right Grant
- 2009-01-26 DK DK09704677.5T patent/DK2252627T3/en active
- 2009-03-05 US US12/398,965 patent/US8546535B2/en active Active
- 2009-03-05 US US12/398,958 patent/US20090233860A1/en not_active Abandoned
-
2010
- 2010-07-25 IL IL207181A patent/IL207181A/en active IP Right Grant
-
2013
- 2013-09-26 US US14/038,631 patent/US9255134B2/en active Active
-
2016
- 2016-01-03 IL IL243446A patent/IL243446B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN102089320A (zh) | 2011-06-08 |
WO2009094634A1 (en) | 2009-07-30 |
ES2633453T3 (es) | 2017-09-21 |
EP2252627B1 (en) | 2017-04-19 |
IL207181A (en) | 2016-09-29 |
BRPI0906404B1 (pt) | 2021-04-06 |
CN102089320B (zh) | 2015-11-25 |
CA2713126C (en) | 2017-08-15 |
KR20100127212A (ko) | 2010-12-03 |
AU2009206212A1 (en) | 2009-07-30 |
JP2011517550A (ja) | 2011-06-16 |
BRPI0906404A2 (pt) | 2015-11-24 |
US8318899B2 (en) | 2012-11-27 |
US9255134B2 (en) | 2016-02-09 |
KR101863136B1 (ko) | 2018-05-31 |
IL207181A0 (en) | 2010-12-30 |
KR20160106191A (ko) | 2016-09-09 |
AU2009206212B2 (en) | 2014-01-16 |
IL243446B (en) | 2021-08-31 |
DK2252627T3 (en) | 2017-08-14 |
US20090233861A1 (en) | 2009-09-17 |
US8546535B2 (en) | 2013-10-01 |
IL243446A0 (en) | 2016-02-29 |
JP5616233B2 (ja) | 2014-10-29 |
PT2252627T (pt) | 2017-07-24 |
CA2713126A1 (en) | 2009-07-30 |
US20140255513A1 (en) | 2014-09-11 |
KR101749310B1 (ko) | 2017-06-21 |
EP2252627A1 (en) | 2010-11-24 |
US20090233860A1 (en) | 2009-09-17 |
US20090269341A1 (en) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0906404B8 (pt) | construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno | |
BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
BRPI0923786C1 (pt) | compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos | |
BR112015009752A2 (pt) | conjugados de anticorpo/fármaco e métodos de uso | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
BR112013031892A2 (pt) | anticorpos anti-psgl-1 e seu uso | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
BR112012005970A2 (pt) | moduladores tricíclicos de proteína quinase | |
BR112014007382A2 (pt) | anticorpos anti-erbb3 e seus usos | |
AR072699A1 (es) | Antagonistas especificos del receptor 4 del factor de crecimiento de los fi-broblastos (fgf-r4) | |
AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
CY1116156T1 (el) | Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο | |
BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
HN2010001761A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
AR089978A1 (es) | Translocaciones de la r-espondina y sus metodos de uso, metodo de tratamiento, antagonistas | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
EA201170659A1 (ru) | Антитела к рецептору ii tgf-вета | |
CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
BR112015010943A2 (pt) | Construtos de fusão hormônio folículo-estimulante (fsh)/domínio lítico e métodos de produção e utilização dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |